Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

[1]  D. Schadendorf,et al.  Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Zalaudek,et al.  Epidemiology and Risk Factors of Melanoma: A Review , 2021, Dermatology practical & conceptual.

[3]  P. Libby,et al.  Interleukins in cancer: from biology to therapy , 2021, Nature Reviews Cancer.

[4]  F. Hodi,et al.  Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma. , 2021 .

[5]  David M. Woods,et al.  Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition , 2020, Journal for immunotherapy of cancer.

[6]  J. Utikal,et al.  Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  You-hong Cui,et al.  CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling , 2019, Laboratory Investigation.

[8]  Yan-Mei Zhang,et al.  Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment , 2019, Cell Death & Disease.

[9]  G. Freeman,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[10]  E. Jaffee,et al.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.

[11]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[12]  K. Wakamatsu,et al.  Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. , 2019, Journal of dermatological science.

[13]  J. Bluestone,et al.  Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer , 2018, Front. Med..

[14]  M. Czyz,et al.  HGF/c-MET Signaling in Melanocytes and Melanoma , 2018, International journal of molecular sciences.

[15]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[16]  P. Ascierto,et al.  Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study , 2018, Cancer Immunology, Immunotherapy.

[17]  Merrick I Ross,et al.  Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.

[18]  Reinhard Dummer,et al.  High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.

[19]  M A Weinstock,et al.  Epidemiology of melanoma. , 2017, Cancer treatment and research.

[20]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[21]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[22]  R. Halaban,et al.  Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Y. Fujisawa,et al.  Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma , 2017, Cancer science.

[24]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[25]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[26]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[27]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[28]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[29]  Carlo Riccardo Rossi,et al.  Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. , 2014, In vivo.

[30]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[31]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[32]  M. Kivimäki,et al.  Chronic inflammation as a determinant of future aging phenotypes , 2013, Canadian Medical Association Journal.

[33]  H. Schmidt,et al.  Interleukin-6 and melanoma , 2012, Melanoma research.

[34]  J. Landsberg,et al.  Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf‐Cdk4R24C C57BL/6 mice , 2011, International journal of cancer.

[35]  G. Debes,et al.  CCL8 and skin T cells—an allergic attraction , 2011, Nature Immunology.

[36]  D. Rigel,et al.  Epidemiology of melanoma. , 2010, Seminars in cutaneous medicine and surgery.

[37]  W. Mars,et al.  Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases , 2010, PloS one.

[38]  Jennifer Urbano Blackford,et al.  Detecting Change in Biological Rhythms: A Multivariate Permutation Test Approach to Fourier‐Transformed Data , 2009, Chronobiology international.

[39]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[40]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[41]  J. Lunceford,et al.  IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .

[42]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.